白蛋白结合型紫杉醇与紫杉醇治疗老年晚期卵巢癌疗效与安全性比较  

Comparison of the effects and safety of abraxane and paclitaxel for advanced ovarian cancer in the elderly

作　　者：关慧[1] 王瑄[2] 关瑞[3] 陈杰[1] 

机构地区：[1]哈尔滨医科大学附属第三医院妇科,黑龙江省哈尔滨市150081 [2]齐齐哈尔市第一医院,黑龙江省齐齐哈尔市161000 [3]哈尔滨医科大学附属第四医院,黑龙江省哈尔滨市150081

出　　处：《实用老年医学》2016年第5期415-417,共3页Practical Geriatrics

基　　金：黑龙江省教育厅科学技术研究项目(12531386)

摘　　要：目的探讨白蛋白结合型紫杉醇与紫杉醇治疗老年晚期卵巢癌的近期疗效及不良反应。方法62例老年晚期卵巢癌患者均经病理证实,按随机数字表法分为2组,A组31例应用白蛋白结合型紫杉醇联合顺铂治疗,B组31例应用普通溶剂型紫杉醇联合顺铂治疗。观察并比较2组的治疗效果和不良反应。结果 A组和B组的治疗总有效率分别为70.9%、64.5%,差异无统计学意义（P〉0.05）;A组患者术后1年和2年生存率分别为74.2%（23/31）、61.3%（19/31）,显著高于B组（54.8%、41.9%）,差异均有统计学意义（P〈0.05）。A组骨髓抑制、腹泻、恶心、呕吐Ⅲ~Ⅳ级的不良反应发生率均低于B组（P〈0.05）,2组神经毒性发生率比较,差异无统计学意义（P〉0.05）。结论白蛋白结合型紫杉醇联合顺铂与紫杉醇联合顺铂治疗老年晚期卵巢癌,均有较好的临床疗效,但白蛋白结合型紫杉醇联合顺铂能明显提高患者的1年和2年生存率,且严重不良反应发生率低,使用方便,值得临床进一步研究。Objective To investigate the short-term efficacy and adverse reactions of abraxane and paclitaxel in the treatment for advanced ovarian cancer in the elderly patients. Methods sixty-two elderly patients with advanced ovarian cancer confirmed by pathology were randomly divided into two groups,according to the random number table. 31 cases of A group treated with abraxane and cisplatin,31 cases of B group treated with paclitaxel plus cisplatin. The effects and adverse reactions of the two groups were observed and compared. Results The total effective rate was 70. 9% and 64. 5% in A group and B group,with no statistically significant difference（ P〉0. 05）; the 1-year and 2-year survival rate of A group was 74. 2%（ 23 /31）,61. 3%（ 19 /31）,which were significantly higher than that in group B（ 54. 8%,41. 9%,P〈0. 05）. The incidence rate of the adverse reactions such as gradeⅢ-Ⅳ of myelosuppression,diarrhea,vomit in A group were lower than those in B group（ P〈0. 05）,and there was no significant difference in neurotoxicity between the two groups（ P〈0. 05）. Conclusions Abraxane or paclitaxel combined with cisplatin in the treatment for advanced ovarian cancer,can both acquire good clinical effect,but the combination of abraxane and cisplatin could acquire higher 1-year and2-year survival rate,and less adverse effects.

关 键 词：老年人 晚期卵巢癌 白蛋白结合型紫杉醇 紫杉醇 

分 类 号：R737.31[医药卫生—肿瘤]